Cabaletta Bio expects to complete $35M stock and warrant sale this week to advance cell therapy candidate


The company's lead cell therapy candidate is being developed to treat multiple autoimmune diseases.

Previous CBJ Morning Buzz: Brian Moynihan for Treasury chief? Bank of America CEO responds — sort of — to report
Next Meridian Bioscience sets closing date for $1.53 billion deal